New hope for advanced breast cancer: combination therapy trial launches
NCT ID NCT07002177
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a common type of advanced breast cancer (ER-positive/HER2-negative) that cannot be removed by surgery or has spread. It tests a new drug called FWD1802 combined with other treatments to find the safest dose and see if it shrinks tumors. About 196 participants will take part across multiple locations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center, Shanghai
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves replace the scalpel for breast tumors?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could gentle yoga and breathing ease Cancer's lingering toll?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?